Velaglucerase alfa

Nature Reviews Drug Discovery

Volumn 9, Issue 11, 2010, Pages 837-838

  Aerts, Johannes M F G ^a   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGLUCERASE; ELIGLUSTAT TARTRATE; GLUCOSYLCERAMIDASE; IMIGLUCERASE; MIGLUSTAT; TALIGLUCERASE ALFA; UNCLASSIFIED DRUG; VELAGLUCERASE ALFA; VPRIV;

ANEMIA; BONE DISEASE; CHEMICAL COMPOSITION; CLINICAL TRIAL; COST OF ILLNESS; DIGESTIVE SYSTEM DISEASE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME REPLACEMENT; FOOD AND DRUG ADMINISTRATION; GAUCHER DISEASE; GENE ACTIVATION; HUMAN; LONG TERM CARE; LYSOSOME STORAGE DISEASE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; THROMBOCYTOPENIA;

CLINICAL TRIALS AS TOPIC; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS;

EID: 78049488936     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3311     Document Type: Short Survey

References (21)

1. Cox, T. M. et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J. Inherit. Metab. Dis. 31, 319-336 (2008).
2. Brady, R. O. Enzyme replacement therapy for lysosomal diseases. Annu. Rev. Med. 57, 283-296 (2006).
3. Barton, N. W. et al. Replacement therapy for inherited enzyme deficiency macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324,1464-1470 (1991).
4. Zimran, A. et al. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 345,1479-1480 (1995).
5. Brumshtein, B. et al. Characterization of gene-activated human acid-b-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 20, 24-32 (2009).
6. US Food and Drug Administration (FDA). FDA labelling information \-Vpriv (velaglucerase alfa). FDA website [online], http://www.accessdata.fda.gov/ drugsatfda-docs/ label/2010/022575lbl.pdf (2010).
7. European Medicines Agency (EMA). European Public Assessment Report \-Vpriv. EMA website [online], http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/001249/ WC500096382.pdf (2010).
8. Zimran, A. et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 11 5 , 4651-4656 (2010).
9. Pastores, G. M. et al. Therapeutic goals in the treatment of Gaucher disease. Semin. Hematol. 41 (Suppl. 5), 4-14 (2004).
10. Elstein, D. et al. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol. Dis. 18 Aug 2010 (doi:10.1016/j.bcmd.2010.07.008).
11. Xu, Y. H. et al. Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. PLoS One 5, e10750 (2010).
12. Hollak, C. E. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol. Dis. 44, 41-47 (2010).
13. Goldblatt. J. et al. Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia. Blood Cells Mol. Dis. 29 May 2010 (doi:10.1016/j.bcmd.2010.05.002).
14. Zimran, A. et al. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply. Blood Cells Mol. Dis. 7 Jun 2010 (doi:10.1016/j.bcmd.2010.05.001)
15. Aviezer, D. et al. A plant-derived recombinant human glucocerebrosidase enzyme a preclinical and Phase I investigation. PLoS One 4, e4792 (2009).
16. Schoonhoven, A. et al. Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin. Chim. Acta 381, 136-139 (2007).
17. Hollak, C.E. Short-term withdrawal from imiglucerase: what can we learn from it? Blood Cells Mol. Dis. 29 May 2010 (doi:10.1016/j.bcmd.2010.05.003).
18. Lukina, E. et al. A Phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 11 6 , 893-899 (2010).
19. Lukina, E. et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: two-year results of a Phase 2 study. Blood 16 Aug 2010 (doi:10.1182/blood-2010-06-293902).
20. IMS MIDAS (IMS Health, 2010).
21. Clark, M. et al. Deutsche Bank Global Markets Research reports on Shire. (Deutsche Bank Global Markets Research, 15 Jun 2010).